Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Roche is going all-in on AI-driven research, announcing plans to build autonomous AI labs as part of a sweeping R&D transformation. The pharma giant aims to bring up to 20 new drugs to market by 2030, with AI already influencing 40% of its pipeline decisions. It's also redirecting $2.41 billion in R&D savings toward productivity and innovation initiatives.
Roche is doubling down on artificial intelligence, unveiling ambitious plans at its pharma investor day to build fully autonomous AI-driven labs designed to accelerate drug discovery and development. The Swiss pharmaceutical giant says it is committed to "AI independence" in R&D — a bold strategic pivot that positions AI not just as a tool, but as a core driver of its research engine.
The company's AI tool, Target Nexus, is on track to contribute to 80% of research portfolio decisions by end of 2026, and Roche recently opened a Boston Innovation Center focused on AI and machine learning applications in drug development.
By the Numbers:
Why it matters: Roche's AI-first strategy signals a broader industry shift toward technology-led drug development — one that could significantly compress timelines, reduce costs, and reshape how new medicines reach patients.
